Hair cloning is being developed by companies like Kangstem Biotech and Stemson, with potential availability in a few years. Initial costs are expected to be high, but prices may decrease over time.
A user is seeking alternatives to finasteride for hair loss during a planned break for family planning reasons. They inquire about pyrilutamide, cosmern, and other potential future treatments.
A new Latanoprost-based formula used by Hollywood celebrities to treat hair loss, with the formula containing minoxidil, tretinoin, melatonin, azelaic acid, zinc thymulin, vitamin B6, sandalore and methyl vanillate. It also mentions the potential of offering a combined sublingual minoxidil/oral dutasteride option in the future.
New hair loss treatments like GT20029 and PP405 could potentially replace minoxidil and finasteride, offering better results with fewer side effects. However, current treatments like finasteride and minoxidil are still effective for many, despite concerns about side effects.
Liposomal carriers for topical finasteride offer better targeting, reduced side effects, and less irritation compared to alcohol-based solutions, but availability and cost may limit their use. Minoxidil can dissolve in liposomal carriers, enhancing delivery and stability.
Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.
Breezula's effectiveness may depend on the vehicle used for its application, with concerns about the grey market version's formulation. Phase 3 results are promising, but skepticism remains about the grey market product's authenticity and effectiveness.
Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.
Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.
Hair loss treatments, including PP405, minoxidil, finasteride, and RU58841, with hopes for future solutions. Participants discuss the emotional impact of hair loss and consider alternatives like hair transplants or acceptance.
Current treatments for hair loss include finasteride, minoxidil, and derma rolling. New treatments like Breezula, PP405, and others are not expected until at least 2027 or later.
PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.
Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.
New potential hair loss treatment uses molecules from hairy moles to stimulate follicle growth. Topical solution requires less frequent application, like Botox injections a few times per year.
User discusses a promising topical Procyanidin B2 treatment for hair loss. Users share mixed experiences and mention effective treatments like finasteride, minoxidil, and LLLT.
P5P supplementation helped reverse finasteride side effects, particularly by lowering prolactin levels and restoring sensitivity. The user experienced significant improvement within a day and full recovery in a few days.
Elastin-based peptides may help reduce wrinkles and could potentially benefit the scalp. The conversation suggests using them with hyaluronic acid gel to improve scalp health and reduce hair fall.
A user is trying to make a topical finasteride solution by crushing tablets into ethanol and glycerin but struggles with spillage. Suggestions include letting the tablets dissolve in the solution or using a pill crusher for efficiency.
The conversation is about the FDA approval of WINLEVI for acne treatment and the anticipation of Breezula, a hair loss treatment using the same active ingredient, which may indicate a positive future for Breezula's release. There is disappointment that Breezula's results are not optimal, but it is seen as progress in hair loss treatment.
The conversation discusses hair loss treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It also references Epibiotech's hair multiplication and cell therapy as potential solutions.
Creating a propylene glycol-free Minoxidil and Tretinoin solution to reduce skin irritation and enhance effectiveness. An emulsifier like lecithin can help mix Tretinoin properly, and Minoxidil foam is an alternative without propylene glycol.
The user is experiencing scalp itching from a PG ethanol base in their hair loss treatment, which includes 0.025% finasteride and 2.5% minoxidil, and is seeking alternatives without PG or ethanol. Suggestions include Zeuss non-PG foam and Ulo, which do not use PG or hydrocortisone.
Rhamnose may promote hair growth and pigmentation, suggesting it as a potential hair loss treatment. The conversation discusses its potential alongside known treatments like Minoxidil, finasteride, and RU58841.
PP405 may induce new hair growth but cannot revive completely dead follicles, and its effectiveness on hairlines is uncertain. It is expected to be available by mid-2028, but users are advised to manage expectations and consider using other treatments like minoxidil and finasteride.
The user wants to make a topical finasteride solution using wound cleanser with 70% IPA and add 40% propylene glycol due to headaches from minoxidil. They seek advice on using the wound cleanser and recommendations for pharmaceutical/cosmetic grade IPA in India.
PP405 and hair cloning are discussed as potential treatments for reversing hair loss from Norwood 7 to Norwood 1. Hair cloning is seen as a more permanent solution, while PP405's effectiveness and long-term effects remain uncertain.
The conversation discusses the hair loss treatment Breezula by Cassiopea, which had a successful Phase II trial and is expected to start Phase III by the end of the year. Users are curious about the timeline for availability and note that it performs slightly better than finasteride at 6 months, slightly worse at 12 months, with the benefit of having no side effects.
Hair loss treatments discussed include promising Pyr available online and Verteporfin dosing after FUE for follicle regeneration, but no updates on SCUBE3.